Navigation Links
Niusule Biotech Corp. to Commence Trading on the OTC Bulletin Board Under the Symbol 'NIUS'
Date:12/30/2008

CARSON CITY, Nev., Dec. 30 /PRNewswire-FirstCall/ -- Niusule Biotech Corp., a Nevada corporation formed on April 8, 2008, announced today that its shares of common stock will begin trading on the OTC Bulletin Board under the symbol "NIUS" on December 30th, 2008.

For a NIUS quote, visit: http://finance.yahoo.com/q?s=NIUS.OB

"Our main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp by manufacturing and selling biopharmaceutical and health food," said Qinghua Hu, Chairman of Niusule Biotech Corp. "We believe our public listing is a signal of Niusule Biotech Corp.'s maturity as a company. I would like to thank Niusule Biotech Corp.'s partners, employees and shareholders for their respective roles in contributing to our success."

In a meeting with employees, directors, and shareholders, Hu discussed Niusule Biotech Corp. goals and priorities as a publicly traded entity including:

    -- Build long-term value for shareholders by implementing our business
       plan;
    -- Seek cooperation and alliance with US companies manufacturing health
       food products for either distribution or production rights in China;
       and
    -- Commitment to being a leading player in China's health food industry
       and bioengineering industry.

"As we are in our initial stages of growth, we provide both small and institutional investors opportunities to invest in China's health food industry," said Hu. "The move to the OTC Bulletin Board positions the company to benefit from greater visibility and liquidity."

About Niusule Biotech Corp.

Founded in 2008, Niusule Biotech Corp.'s main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp. Niusule Biotech Corp. is trying to build a bridge between the USA and China in the health food industry and bioengineering industry by accessing the talent pools in both countries and by applying the mature technologies and high quality standards of the USA to its business model in China.

For more information about Niusule Biotech Corp., visit http://www.niusule.com.

This news release contains forward-looking statements. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks described in the company's filings with the SEC.


'/>"/>
SOURCE Niusule Biotech Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
4. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
5. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
6. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
7. Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
8. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
9. Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
10. Micromet Added to NASDAQ Biotechnology Index
11. Biotech Endorsement Insurance Discount Expanded to Nebraska, Kansas Growers Planting Corn with HERCULEX XTRA Traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/6/2017)... ... October 06, 2017 , ... On ... and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The ... The event is free and open to the public, but registration is required. ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):